ArticleMolecular biology reports2026
Neem leaf glycoprotein mediated immunomodulation and epigenetic regulation in Acute Myeloid Leukemia.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is associated with impaired antitumor immunity and defective activation of protective immune cells. Neem leaf glycoprotein (NLGP), an immunomodulatory component of neem leaf preparation, has demonstrated antitumor activity in several experimental models without apparent toxicity. This study investigated the immunomodulatory and epigenetic effects of NLGP on immune cells involved in tumor protection in AML.
methodsPeripheral immune cells from healthy individuals and AML patients were treated with NLGP. CD33 negative lymphocytes from AML patients were evaluated for lymphocyte proliferation, immune-cell activation, and secretion of the Th1-associated cytokines IFN-γ and TNF-α. Nitric oxide (NO₂⁻) release and reduced glutathione (GSH) content were also measured. The expression of Th1- and tumor-suppression-associated genes was analyzed. Chromatin immunoprecipitation was used to assess enrichment of active histone marks, including H3K4me3 and H3K14Ac, and repressive or regulatory markers, including H3K27me3, HDAC1, p53, Notch1, and c-Myc, at the IFNG and TBX21 loci. Cytotoxic T-lymphocyte (CTL)-mediated killing of AML cells was also examined.
resultsNLGP enhanced lymphocyte proliferation and activated multiple immune-cell populations in normal subjects and AML-derived CD33 negative lymphocytes. It increased IFN-γ, TNF-α, and NO₂⁻ production while reducing GSH content. NLGP upregulated genes associated with Th1 immunity and tumor suppression. At the IFNG and TBX21 loci, it increased enrichment of H3K4me3, H3K14Ac, and p53, while reducing H3K27me3, HDAC1, Notch1, and c-Myc enrichment. NLGP also stimulated CTLs and enhanced their ability to eliminate AML cells.
conclusionNLGP promotes tumor-protective immunity in AML through coordinated immune activation and epigenetic regulation, supporting its potential as a novel adjunctive immunotherapeutic strategy.
Indexed as
Identifiers
42690245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.